CN111465598A - 作为SGLTs抑制剂的葡糖苷类衍生物及其应用 - Google Patents

作为SGLTs抑制剂的葡糖苷类衍生物及其应用 Download PDF

Info

Publication number
CN111465598A
CN111465598A CN201980006377.9A CN201980006377A CN111465598A CN 111465598 A CN111465598 A CN 111465598A CN 201980006377 A CN201980006377 A CN 201980006377A CN 111465598 A CN111465598 A CN 111465598A
Authority
CN
China
Prior art keywords
compound
group
isomer
pharmaceutically acceptable
reaction
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201980006377.9A
Other languages
English (en)
Other versions
CN111465598B (zh
Inventor
吴成德
毛庆华
李翼
于涛
陈曙辉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shandong Danhong Pharmaceutical Co Ltd
Original Assignee
Shandong Danhong Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shandong Danhong Pharmaceutical Co Ltd filed Critical Shandong Danhong Pharmaceutical Co Ltd
Publication of CN111465598A publication Critical patent/CN111465598A/zh
Application granted granted Critical
Publication of CN111465598B publication Critical patent/CN111465598B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/351—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom not condensed with another ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/10—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

一类作为SGLT1/SGLT2双重抑制剂的葡糖苷类衍生物，及其在制备作为SGLT1/SGLT2双重抑制剂的药物中的应用，所述衍生物为式(Ⅰ)所示化合物、其异构体或其药学上可接受的盐。

Description

PCT国内申请，说明书已公开。

Claims (19)

  1. PCT国内申请，权利要求书已公开。
CN201980006377.9A 2018-03-30 2019-03-29 作为SGLTs抑制剂的葡糖苷类衍生物及其应用 Active CN111465598B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201810291288 2018-03-30
CN2018102912880 2018-03-30
PCT/CN2019/080436 WO2019185026A1 (zh) 2018-03-30 2019-03-29 作为SGLTs抑制剂的葡糖苷类衍生物及其应用

Publications (2)

Publication Number Publication Date
CN111465598A true CN111465598A (zh) 2020-07-28
CN111465598B CN111465598B (zh) 2023-04-21

Family

ID=68060961

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980006377.9A Active CN111465598B (zh) 2018-03-30 2019-03-29 作为SGLTs抑制剂的葡糖苷类衍生物及其应用

Country Status (2)

Country Link
CN (1) CN111465598B (zh)
WO (1) WO2019185026A1 (zh)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022253334A1 (zh) * 2021-06-04 2022-12-08 南京明德新药研发有限公司 一种raf激酶抑制剂的晶型及其制备方法

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220153772A1 (en) * 2019-03-29 2022-05-19 Medshine Discovery Inc. Glucoside derivative that acts as sglt1 inhibitor and application thereof
US20230046018A1 (en) * 2019-12-06 2023-02-16 Medshine Discovery Inc. Biaryl compound as pan-raf kinase inhibitor
CN113912591B (zh) * 2020-07-08 2023-10-20 齐鲁制药有限公司 联芳基化合物
WO2022063305A1 (zh) * 2020-09-27 2022-03-31 南京明德新药研发有限公司 葡糖苷类化合物的晶型及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093610A1 (en) * 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
CN102875503A (zh) * 2011-06-25 2013-01-16 山东轩竹医药科技有限公司 C-糖苷衍生物

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2369016T3 (es) * 2006-02-15 2011-11-24 Boehringer Ingelheim International Gmbh Derivados de benzonitrilo sustituidos por glucopiranosilo, composiciones farmacéuticas que contienen tales tipos de compuestos, su uso y procedimiento para su fabricación.
CN101384576A (zh) * 2006-02-15 2009-03-11 贝林格尔.英格海姆国际有限公司 被吡喃型葡萄糖基取代的苯甲腈衍生物、含此化合物的药物组合物、其用途及其制备方法
CN101503399B (zh) * 2008-02-04 2012-06-27 白鹭医药技术（上海）有限公司 C-芳基葡萄糖苷sglt2抑制剂
WO2012109996A1 (zh) * 2011-02-18 2012-08-23 上海璎黎科技有限公司 一种芳基糖苷类化合物及其制备方法和应用
CN104109154A (zh) * 2013-04-17 2014-10-22 上海阳帆医药科技有限公司 C-芳基葡萄糖苷衍生物及其制备方法和应用
CN104761522B (zh) * 2014-01-03 2017-02-15 山东轩竹医药科技有限公司 光学纯的苄基‑4‑氯苯基的c‑糖苷衍生物
CN105001213B (zh) * 2014-04-14 2020-08-28 上海迪诺医药科技有限公司 C-芳基糖苷衍生物、其药物组合物、制备方法及应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007093610A1 (en) * 2006-02-15 2007-08-23 Boehringer Ingelheim International Gmbh Glucopyranosyl-substituted benzonitrile derivatives, pharmaceutical compositions containing such compounds, their use and process for their manufacture
CN102875503A (zh) * 2011-06-25 2013-01-16 山东轩竹医药科技有限公司 C-糖苷衍生物

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022253334A1 (zh) * 2021-06-04 2022-12-08 南京明德新药研发有限公司 一种raf激酶抑制剂的晶型及其制备方法

Also Published As

Publication number Publication date
CN111465598B (zh) 2023-04-21
WO2019185026A1 (zh) 2019-10-03

Similar Documents

Publication Publication Date Title
CN111465598A (zh) 作为SGLTs抑制剂的葡糖苷类衍生物及其应用
CN111372930B (zh) 一种SGLTs抑制剂及其应用
CN110446712B (zh) 作为A2A受体抑制剂的[1,2,4]三唑并[1,5-c]嘧啶衍生物
CN115698022A (zh) 五元杂芳并咪唑类化合物及其应用
EP3536698B1 (en) Lanosterol prodrug compound and use thereof
CN110546149B (zh) 作为pcsk9抑制剂的哌啶类化合物
CN111683928B (zh) 作为fgfr抑制剂的吡嗪-2(1h)-酮类化合物
EP3444247B1 (en) Pyridone derivative comprising oxetane substituent, for treating fibrosis and inflammatory diseases
CN111344290A (zh) 作为Wee1抑制剂的大环类化合物及其应用
CN113061144A (zh) 氮杂环丁烷衍生物
CN113227051A (zh) 用于视网膜疾病的化合物
CN114450289B (zh) 作为选择性btk激酶抑制剂的吡唑并吡啶类化合物
JP2021510164A (ja) Ｃｘｃｒ２アンタゴニスト
CN111247161B (zh) 用作iap抑制剂的smac模拟物及其用途
CN111556869A (zh) 作为csf-1r抑制剂的杂环化合物及其应用
CN109071469B (zh) 三环类化合物及其应用
CN113825750B (zh) 作为sglt1抑制剂的葡糖苷类衍生物及其应用
CN112888686B (zh) 噻二唑衍生物及其作为gls1抑制剂的应用
CN110741003B (zh) 作为gls1抑制剂的化合物

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant